key: cord-0985320-xbk2blda
authors: Feemster, Agnes Ann; Augustino, Melissa; Duncan, Rosemary; Khandoobhai, Anand; Rowcliffe, Meghan
title: Use of failure modes and effects analysis to mitigate potential risks prior to implementation of an intravenous compounding technology
date: 2021-04-23
journal: Am J Health Syst Pharm
DOI: 10.1093/ajhp/zxab179
sha: 213e79b7678095c538130e624a170c0fb9e3e6b6
doc_id: 985320
cord_uid: xbk2blda

DISCLAIMER: In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. PURPOSE: The purpose of this study was to identify potential failure points in a new chemotherapy preparation technology and to implement changes that prevent or minimize the consequences of those failures before they occur using the failure modes and effects analysis (FMEA) approach. METHODS: An FMEA was conducted by a team of medication safety pharmacists, oncology pharmacists and technicians, leadership from informatics, investigational drug, and medication safety services, and representatives from the technology vendor. Failure modes were scored using both Risk Priority Number (RPN) and Risk Hazard Index (RHI) scores. RESULTS: The chemotherapy preparation workflow was defined in a 41-step process with 16 failure modes. The RPN and RHI scores were identical for each failure mode because all failure modes were considered detectable. Five failure modes, all attributable to user error, were deemed to pose the highest risk. Mitigation strategies and system changes were identified for 2 failure modes, with subsequent system modifications resulting in reduced risk. CONCLUSION: The FMEA was a useful tool for risk mitigation and workflow optimization prior to implementation of an intravenous compounding technology. The process of conducting this study served as a collaborative and proactive approach to reducing the potential for medication errors upon adoption of new technology into the chemotherapy preparation process.

A c c e p t e d M a n u s c r i p t Am J Health-Syst Pharm. 2021;78(x):xxx-xxx Parenteral chemotherapeutic agents are considered high-risk medications, and errors in preparation may result in dire consequences. In one study, antineoplastic agents were cited as the second most common source of fatal medication errors. 1 The narrow therapeutic index and significant toxicities of these medications-and the vulnerability of patients receiving them-make preparation of precise doses critical. Incorrect dosages accounted for 38 of 141 errors identified in a study conducted in a large community hospital oncology ward. 2 The error rate for intravenous (IV) compounding without IV workflow technology in US hospital pharmacies has been reported as 9%, with incorrect doses accounting for the majority of errors. 3 IV workflow management systems and IV robotics are the 2 types of automation technologies that are currently being used to reduce errors associated with compounding IV chemotherapy agents. These technologies utilize barcode scanning and image capture to ameliorate common sources of error associated with traditional IV compounding, such as incorrect drug or diluent selection and incorrect volumes withdrawn. Incorporation of gravimetric detection to the IV workflow system provides an additional safeguard compared to traditional volumetric verification processes such as the syringe pull-back method. The benefits of these IV workflow systems for improving the safety of IV preparation and reducing waste have been documented. 4 IV workflow systems utilizing gravimetric verification were shown to detect medication dosing errors in nearly 8% of prepared chemotherapy doses and prevent these errors from reaching patients. 5 Changing pharmacy workflow can have unintended consequences, as staff could be unfamiliar with the potential risks for error with implementation of a new system. In order A c c e p t e d M a n u s c r i p t to prevent risks associated with the adoption of a new IV workflow technology, proactive measures can be utilized to ensure that patients are not exposed to these foreseeable risks.

The Institute for Healthcare Improvement's failure modes and effects analysis (FMEA) tool was used to identify steps in a new workflow, determine the potential for errors in those steps, and predict the likelihood of those errors to cause harm. 6 This tool has been validated previously, and the importance of risk management in the deployment of new medical technologies is known. 7, 8 FMEAs have been previously conducted with a focus on smart infusion pumps, pediatric drug prescribing and administration, computerized order entry systems, and the prevention of controlled substance diversion. [9] [10] [11] [12] Furthermore, previous experience using the FMEA tool at our medical center prior to deployment of a chemotherapy IV robot yielded positive results. Therefore, prior to implementation of a new IV workflow system for manual admixture of hazardous medications, a an FMEA was conducted over a 13-month period in order to define the workflow for use, identify opportunities for error and their risk potential, and develop system and operational changes to mitigate risks.

The FMEA was performed between February 2018 and February 2019 by a team consisting of medication safety pharmacists; oncology pharmacists and technicians; members of the leaderships of the informatics, investigational drug, and medication safety services; and representatives from the technology vendor.

The objective of the initial phase of the analysis was to outline the process for using the technology. After each step of the process was defined, potential failures in the process A c c e p t e d M a n u s c r i p t were identified. Each failure mode was then evaluated for severity based on clinical and operational impact, frequency, and detectability.

Failure modes were scored using both Risk Priority Number (RPN) and Risk Hazard Index (RHI) scores ( Table 1 ).

The RPN is the numeric product of the failure mode severity, frequency, and detectability scores. Clinical severity was scored between 1 (no harm) and 4 (death or major loss of function); production severity was scored between 1 (downtime of less than 30 minutes) and 4 (downtime greater than 4 hours). Frequency scores were between 1 (remote; likely to occur once every year at most) and 4 (frequent; likely to occur daily).

Failure modes were considered as either detectable (score of 1) or undetectable (score of 4). RPN values were calculated for each failure mode using the following equation: RPN = CS × OS × F × D, where CS indicates clinical severity; OS, operational severity; F, frequency; and D, detectability. The minimum RPN score for a mode was 1, while a maximum score was 256. The RPN prioritizes the failure modes in order to guide the allocation of resources to address the highest-priority failures; higher RPN values indicate higher risk and priority.

The RHI assigns each failure mode to a risk category based upon severity and frequency. RHI values were calculated for each failure mode using the following equation: RHI = CS × OS × F. The minimum RHI score for a mode was 1, while a maximum score was 64. Higher RHI values signify severe failures that occur frequently and are considered a greater risk (ie, high risk).

After the modes were scored using both RPN and RHI, the modes considered high risk were addressed. In the analysis, modes were considered high risk if the RPN or RHI score was 9 or higher. Interventions were identified for the high-risk modes. The RPN and RHI scores were recalculated based on the prospective impact of the intervention.

A c c e p t e d M a n u s c r i p t

The vendor provided 2 product demonstrations and developed a video recording of the IV compounding technology in use. The ability to consult the recording and the expertise of the staff members who were familiar with the vendor's chemotherapy compounding robot, which has similar features, were critical in developing the 41-step workflow process.

After the expected workflow was defined, each step was examined for error potential. A total of 16 failure modes were identified. Each mode was scored using both RPN and RHI scores ( Table 2) , and those deemed the highest-risk modes were highlighted. In the exercise, the RPN and RHI scores were identical for each failure mode because all modes were considered detectable (score of 1).

Each of the 5 highest-risk modes (those with RPN and RHI scores of 9) were further assessed. The ability to advance through the product preparation process is prohibited by the system design in 3 of the 5 modes. Because a staff member encounters a hard stop and cannot proceed, actions were not identified for these 3 modes. For the 2 remaining failure modes, mitigation strategies and system changes were identified. The system modification requests included a change to less ambiguous terminology within the software, as well as implementation of a photo preview option for the technician after photographs of the final product and ingredients are taken. Both modifications were submitted to the vendor and completed prior to implementation of the technology and resulted in lower RPN and RHI scores (6 for both). A site-specific procedural change consisted of a policy statement that technicians must alert the pharmacist of any dose discrepancies of ±5% of the ordered dose. c c e p t e d M a n u s c r i p t review of the syringe image by the pharmacist. When the technology is used in this way, gravimetric analysis functions as the primary method to determine dose accuracy, with electronic image capture enabling additional confirmation. The team weighed the potential for delays in product preparation while awaiting pharmacist verification of the electronic image with the ability to intercept dosage errors prior to product injection. It was determined that employing image capture as a historical record of the preparation that can be consulted if concerns in preparation exist rather than as a mechanism for real-time verification was an appropriate use of the technology.

An unintended consequence of the decision to use image capture as a secondary source of dose confirmation was recognized after implementation of the technology in one of the health system's affiliated infusion centers. Prior to use of the technology, the pharmacist was required to visually inspect the syringe volume prior to injection of the medication into the final product container. It was expected that staff would resume the practice of a visual review of the syringe contents prior to injection if a technology failure occurred and manual preparation was required; however, staff implemented the syringe pull-back method to determine dose accuracy. We suspect that staff felt comfortable with the syringe pull-back approach because the technology workflow allowed for visual inspection of the syringe contents after, rather than during, product preparation.

While there are a number of different IV workflow management systems, the FMEA approach described in this article is applicable to any institution that identifies this technology as the most suitable for its infusion preparation process. In cases of institutions utilizing different IV workflow systems in chemotherapy preparation, the described FMEA method may serve as a template for risk stratification and mitigation prior to implementation.

A c c e p t e d M a n u s c r i p t

An FMEA conducted prior to implementation of an IV compounding technology is a useful tool to address future workflow issues and identify potential failure modes within the dispensing process. Inclusion of vendor representatives in the analysis is recommended, particularly when analyzing workflows where there is limited experience with the technology. A collaborative approach may also allow for system changes to reduce risks prior to product implementation. The project described here can serve as a template for others conducting FMEA of a new technology.

The authors have declared no potential conflicts of interest. M a n u s c r i p t M a n u s c r i p t 

Retrospective analysis of mortalities associated with medication errors

Study of medication errors on a community hospital oncology ward

Observational study of accuracy in compounding i.v. admixtures at five hospitals

The impact of using an intravenous workflow management system (IVWMS) on cost and patient safety

Evaluation of real-time data obtained from gravimetric preparation of antineoplastic agents shows medication errors with possible critical therapeutic impact: results of a large-scale, multicentre, multinational, retrospective study

Institute for Healthcare Improvement. Failure modes and effects analysis (FMEA) tool

Failure mode and effects analysis outputs: are they valid

Association for the Advancement of Medical Instrumentation; American National Standards Institute; and International Organization for Standardization

Using failure mode and effects analysis to plan implementation of smart intravenous pump technology

Use of FMEA analysis to reduce risk of errors in prescribing and administering drugs in paediatric wards: a quality improvement report

A risk analysis method to evaluate the impact of a computerized provider order entry system on patient safety

Controlled substance diversion in health systems: a failure modes and effects analysis for prevention

Classical failure modes and effects analysis in the context of smart grid cyber-physical systems

US Department of Veterans Affairs. Healthcare Failure Mode and Effect Analysis (HFMEA)

THRIV Coalition for IV Accuracy

M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t